Inhaled laninamivir octanoate as prophylaxis for influenza in children

Pediatrics

Volumn 138, Issue 6, 2016, Pages

  Nakano, Takashi ^a   Ishiwada, Naruhiko ^b   Sumitani, Tokuhito ^c   Uemori, Mitsutoshi ^c   Isobe, Koji ^c  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LANINAMIVIR OCTANOATE; OSELTAMIVIR; PLACEBO; ZANAMIVIR; ANTIVIRUS AGENT; LANINAMIVIR;

ARTICLE; BRONCHITIS; CHILD; CHRONIC RESPIRATORY TRACT DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROENTERITIS; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; HUMAN EXPERIMENT; INFECTION PREVENTION; INFLUENZA; INFLUENZA A (H3N2); JAPAN; MALE; MULTICENTER STUDY; PHARYNGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK REDUCTION; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; AGE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMMUNICABLE DISEASE CONTROL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FAMILY SIZE; FOLLOW UP; INFLUENZA, HUMAN; INHALATIONAL DRUG ADMINISTRATION; PHYSIOLOGIC MONITORING; PROCEDURES; RISK ASSESSMENT;

ADMINISTRATION, INHALATION; AGE FACTORS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FAMILY CHARACTERISTICS; FOLLOW-UP STUDIES; HUMANS; INFLUENZA, HUMAN; JAPAN; MONITORING, PHYSIOLOGIC; RISK ASSESSMENT; TREATMENT OUTCOME; ZANAMIVIR;

EID: 85008315212     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2016-0109     Document Type: Article

References (28)

1. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333-1340
2. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342(4):232-239
3. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics. 2004;113(3 pt 1):585-593
4. Tanabe T, Hara K, Nakajima M, Shimakawa S, Tamai H. Oseltamivir treatment for children showing abnormal behavior during influenza virus infection. Brain Dev. 2010;32(6):440-444
5. Nakamura Y, Sugawara T, Ohkusa Y, et al. Abnormal behavior during influenza in Japan during the last seven seasons: 2006-2007 to 2012-2013. J Infect Chemother. 2014;20(12):789-793
6. Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf. 2008;31(12):1097-1114
7. Nobuhara H, Watanabe Y, Miura Y. Estimated influenza vaccination rates in Japan [in Japanese]. Nippon Koshu Eisei Zasshi. 2014;61(7):354-359
8. Lopes E Souza TM, Fintelman-Rodrigues N, Resende PC, et al. Oseltamivirresistant influenza A (H1N1) pdm2009 strains found in Brazil are endowed with permissive mutations, which compensate the loss of fitness imposed by antiviral resistance. Mem Inst Oswaldo Cruz. 2015;110(1):101-105
9. Takashita E, Kiso M, Fujisaki S, et al. Characterization of a large cluster of influenza A (H1N1) pdm09 viruses crossresistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan. Antimicrob Agents Chemother. 2015;59(5):2607-2617
10. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother. 2009;53(1):186-192
11. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460(7258):1021-1025
12. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y; MARVEL Study Group. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51(10):1167-1175
13. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54(6):2575-2582
14. Watanabe A. A randomized doubleblind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. J Infect Chemother. 2013;19(1):89-97
15. Katsumi Y, Otabe O, Matsui F, et al. Effect of a single inhalation of laninamivir octanoate in children with influenza. Pediatrics. 2012;129 (6). Available at: www.pediatrics.org/cgi/content/full/129/6/e1431
16. Kashiwagi S, Watanabe A, Ikematsu H, et al. Laninamivir octanoate for postexposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. J Infect Chemother. 2013;19(4):740-749
17. International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Guideline: Guideline for Good Clinical Practice E6 (R2). Current Addendum Step 2 version dated June 11, 2015. Available at: www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R2-Addendum-Step2.pdf. Accessed August 7, 2015
18. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Clinical Investigation of Medicinal Products in the Pediatric Population Recommended for Adoption at Step 4 of the ICH Process on July 20, 2000 by the ICH Steering Committee. Available at: https://www.pmda. go. jp/files/000156792.pdf. Accessed August 7, 2015
19. Kuroki H. Inhalation of long-acting neuraminidase inhibitor laninamivir octanoate in younger age groups [in Japanese]. The Japanese Journal of Clinical and Experimental Medicine. 2012;89(11):1606-1610
20. Nakauchi M, Yasui Y, Miyoshi T, et al. One-step real-time reverse transcription-PCR assays for detecting and subtyping pandemic influenza A/H1N1 2009, seasonal influenza A/H1N1, and seasonal influenza A/H3N2 viruses. J Virol Methods. 2011;171(1):156-162
21. Yokota S. Grants-in-aid for scientific research, Research reports in 2005: Study on the occurrence of accompanying symptoms of influenza virus infection [in Japanese]. Available at: www.mhlw. go. jp/topics/2006/10/dl/tp1020-2.pdf. Accessed April 25, 2016
22. Kashiwagi S. Review of laninamivir octanoate for the postexposure prophylaxis against influenza. [in Japanese] Japanese Journal of Chemotherapy. 2013;61(6):492-503
23. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004;189(3):440-449
24. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 2004;103(1-2):199-203
25. World Health Organization. Annex 3 Recommendations for the production and control of influenza vaccine (inactivated). Published 2005. Available at: www.who. int/biologicals/publications/trs/areas/vaccines/influenza/ANNEX 3 InfluenzaP99-134.pdf?ua=1. Accessed August 9, 2016
26. Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med. 2012;156(7):500-511
27. Watanabe A. Diagnostic issues: Points to consider when diagnosing the common cold syndrome [in Japanese]. Japanese Journal of Clinical and Experimental Medicine. 2000;77(12):2235-2238
28. Inavir Dry Powder Inhaler [package insert]. Tokyo, Japan: Daiichi Sankyo Co, Ltd; 2015 (revised)